MF

Mubeen Fatima Sayad Aref Ali

Active Director Director DIN 09249163
DIN 09249163 First appointment Jul 2021 Primary industry Trading
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Mubeen Fatima Sayad Aref Ali

Data last updated:

Mubeen Fatima Sayad Aref Ali is a Director at Pharmalink Pharmaceuticals Private Limited (since 2021). The company operates in Trading.

DIN 09249163
Primary Designation Director
Industry Trading
First Appointment 22 Jul 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Jul 20212021Active

Board colleagues of Mubeen Fatima Sayad Aref Ali

NameDINCompanyDesignation
Iftequar Ali Syed09249022Pharmalink Pharmaceuticals Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Pharmalink Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Mubeen Fatima Sayad Aref Ali

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mubeen Fatima Sayad Aref Ali

Mubeen Fatima Sayad Aref Ali currently holds 1 directorship: Pharmalink Pharmaceuticals Private Limited (Director, since 22 Jul 2021).

Mubeen Fatima Sayad Aref Ali was first appointed on 22 Jul 2021 as Director at Pharmalink Pharmaceuticals Private Limited.

The current boards of Mubeen Fatima Sayad Aref Ali's companies include Iftequar Ali Syed (Pharmalink Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available